
|Articles|September 25, 2000
Early Approval for Abbott AIDS Medicine
Advertisement
(ABBOTT PARK, ILL)The Food and Drug Administration (FDA) has granted an early approval of the Abbott Laboratories' AIDS drug Kaletra, a form of protease inhibitor medication that has shown considerable promise in bringing the virus down to undetectable levels. Abbott applied for FDA approval on June 1, 2000 and was not expecting results until later this fall.
Kaletra is a mixture of two drugs, the main one generically called lopinavir and previously called ABT-378 in Abbott clinical labs, the other is ritonavir, already on the market as an AIDS drug under the brand name Norvir. For more information visit www.fda.gov.
Advertisement
Advertisement
Advertisement
Trending on Infection Control Today
1
Infectious Disease Doctor Discusses Hantavirus Outbreak and Public Health Preparedness, Misinformation, and Emerging Disease Threats
2
UV-C as a Critical Second Step in Reducing HAIs: Why Adjunct Disinfection Is a Strategic Investment in High-Risk Health Care Environments
3
Sterile Processing Under Pressure: What Penn State Health’s Instrument Sterilization Crisis Reveals About Patient Safety Risks
4
PASTEUR Act, NDM-CRE Surge, and the Cost of Inaction: What Infection Preventionists Need to Know About Antibiotic Policy and AMR
5




